Saxagliptin, a selective and reversible DPP-4 (dipeptidyl peptidase-4) inhibitor, functions by inhibiting the DPP-4 enzyme. This slows down the degradation of GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide), thereby increasing their plasma concentrations. This enhanced level promotes glucose-dependent insulin secretion and decreases glucagon levels, ultimately regulating blood glucose levels.
Indications:
Saxagliptin is primarily used for glycemic control in patients with type 2 diabetes, particularly when diet and exercise fail to adequately manage blood sugar levels. It can be used as monotherapy or in combination with other antidiabetic agents.